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the direct treatment of respiratory infections, but also for
the treatment of co-morbid medical conditions of respira-
tory infections patients. These costs also vary consider-
ably by type of respiratory infection. The study also
shows that respiratory infections impose substantial indi-
rect costs on employers from work loss associated with
these infections.
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OBJECTIVES: To examine the relationship between self-
reported health status, prophylactic medication utiliza-
tion, and health care service utilization in older adults
with asthma. METHODS: Design: A prospective longitu-
dinal cohort study was conducted over a 2-year post-
enrollment period in a population of managed care enrolled
asthmatic older adults. Patients completed a comprehen-
sive health risk screen at time of enrollment in the plan.
Setting: A Medicare HMO in the Southeastern United
States with prescription benefit. Participants: A total of
129 Medicare-HMO enrolled older adults with asthma
using inhaled corticosteroid therapy as prophylaxis were
available for complete follow up. Measurements: We
measured self-reported health perception, falls, lifestyle,
depressive symptomatology, and pre-enrollment health
care service use using a comprehensive risk screen. We
used the medication possession ratio and total annual
health care charges as measures of post-enrollment in-
haled corticosteroid and health care service use. RE-
SULTS: After adjusting for the effects of other variables
we found that depressive symptomatology (DS) at base-
line and increased comorbidity severity (using the Charl-
son comorbidity index) were associated with significant
reductions in prophylactic medication possession (27%
with DS, and 6% with unit increase in Charlson’s index,
p  0.05). Additionally we found, after adjusting for the
effects of baseline health status, a 10% increase in pro-
phylactic medication possession was associated with a
5% decrease in total annual health care charges in this
population (p  0.05). CONCLUSIONS: There seem to
be strong associations between poor health status at time
of enrollment, decreased post-enrollment prophylactic
medication use and increased post-enrollment health care
service utilization in older adults with asthma.
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OBJECTIVES: The purpose of this study is to adapt a
previously validated questionnaire to a pharmacy claims
database and examine its construct validity in measuring
severity of illness in chronic respiratory disease (CRD).
METHODS: The authors modified an asthma severity of
illness questionnaire (13 items, total score range 0–28)
based upon symptoms, medication use, hospitalization
information and intubation history to a scale that is more
conducive to retrospective data analysis. The adapted
CRD scale (CRDS) was based on pharmacy claims data
and hospitalization history (11 items, total score range 0–
18). The CRDS was compared to utility as measured by a
general health visual analogue scale and quality of life
(QoL) as measured by the Physical Component Scale
(PCS), Physical Function (PF) and General Health (GH)
domains of the SF-36. Panel data analysis was performed
on pharmacy claims and survey data from the Kaiser Per-
manente/USC Consultation Study. QoL and utility were
regressed on the CRDS, along with covariates. A non-res-
piratory chronic disease score was used to control for
chronic disease while avoiding significant multicollinear-
ity. The analysis was limited to 126 patients with CRD
followed over 3 years. The Hausman specification test
was used to determine the appropriateness of the ran-
dom-effects model formulation. RESULTS: The Haus-
man specification test suggested the use of the fixed-
effects formulation for utility (m  8.2, p  m  0.0420).
The CRDS was negative and significant (1.79, p 
0.0286). The Hausman test suggested a fixed-effects for-
mulation for PCS (p  m  0.0333) and random-effects
for GH (p  m  0.0628) and PF (p  m  0.1495). The
CRDS was significant and negative for all three QoL do-
mains: (PCS: 0.68, p  0.0085; PF: 0.97, p0.0130;
GH: 0.065, p  0.0077). CONCLUSION: The adapta-
tion of the asthma severity of illness questionnaire ap-
pears to be a valid measure of chronic respiratory disease
in a pharmacy claims database.
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OBJECTIVES: Adult patients with moderate to severe
asthma could potentially avoid utilizing excessive health
care resources by reducing the need for management of
severe adverse effects associated with albuterol. This
modeled analysis was performed from a managed care
payer perspective to determine if nebulized levalbuterol is
associated with a lower cost per decreased use of rescue
inhaler, as compared with nebulized racemic albuterol
over a four week period. METHODS: Cost data was ob-
tained from a public hospital, an HMO, and the Red
Book. Costs were measured in 2000 US dollars. Probabil-
ities were derived from a clinical controlled trial and the
National Center for Health Statistics. The primary out-
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come of interest was cost per decreased puff of rescue
medication per twenty eight days. RESULTS: Leval-
buterol (1.25 mg) decreased puffs by 7.5 over twenty
eight days. However, the average expected costs for treat-
ment with racemic albuterol (2.5 mg) is $116.94/month,
$171.46/month for levalbuterol (0.63 mg) and $182.33/
month for levalbuterol (1.25 mg). Cost-effectiveness ra-
tios were $8.35, $24.50, and $8.80 for albuterol (2.5
mg), levalbuterol (0.63 mg) and levalbuterol (1.25 mg),
respectively. Results were unchanged after sensitivity
analyses. CONCLUSIONS: Levalbuterol (1.25 mg) was
beneficial over racemic albuterol (2.5 mg) in decreasing
puffs of rescue medication over twenty eight days, but at
an additional cost. An incremental cost-effectiveness anal-
ysis demonstrated it costs $9.73 for each additional de-
creased puff per day. The decision-maker needs to evalu-
ate whether the additional effect is worth the added cost.
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OBJECTIVES: Despite their complexity appropriate use of
asthma inhaled medicines is crucial to ensure optimal drug
delivery to the airways. We describe the validation of an
instrument to assess inhalation skills in children. METH-
ODS: The instrument includes a breakdown of the steps
necessary for appropriate inhalation. We videotaped 25
children taking a placebo inhaler (metered dose inhaler
(MDI), MDI with AeroChamber® (MDI-AE®), and Dis-
kus®). A gold standard (GS) was developed by agreement
of two asthma experts watching the videotaped demon-
strations. Twenty-one raters scored the randomly ordered
demonstrations twice within a 2-week interval (sessions 1
and 2). Intra-class correlation coefficients (ICCs) were cal-
culated to assess validity (comparing GS to raters’ scores),
interrater reliability, and test-retest reliability for each step
of the inhalation. RESULTS: ICCs varied considerably by
both, the device and the step. In session 1, a small propor-
tion of raters agreed with the GS on whether patients actu-
ated the MDI and inhaled simultaneously (9.5%, ICCs
0.62 to 0.74) and whether patients hold their breath
(19%, ICCs 0.62 to 1.00). A better agreement was ob-
served for the MDI-AE® where actuation (43%, ICCs
0.43 to 0.56) and inhalation (57%, ICCs 0.43) are two
separate steps. The best interrater agreement was on the
shaking of the MDI (ICC  0.83) and the MDI-AE®
(ICC  0.74). Agreement for the Diskus® was poor for
all steps. Results for session 2 were similar. The best in-
tra-rater agreement was for the Diskus® (ICCs  1 for 5
steps), though only a small proportion of raters agreed on
these steps (5% to 21%). CONCLUSIONS: There was
large variability within and between raters’ scores. Some
steps were better assessed than others. These results sug-
gest that in addition to a detailed instrument, training of
raters is crucial to obtain a valid assessment of the child-
rens’ inhalation technique.
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OBJECTIVES: The study involved validating the scaling
properties of patient-physician interaction scale in a pul-
monary specialty clinic using a clinic-specific scale
through the implementation of Rasch analysis. DATA:
Cross-sectional data from 65 adult asthma patients at the
University of Illinois Asthma clinic was used. Physician
interaction was measured using eight Likert-type items.
Patients responded from “strongly disagree” (1) to
“strongly agree” (4). METHODS: Scaling properties
were assessed by investigating its fit to a Partial Credit
Rasch Rating scale model that enabled item-by-item anal-
ysis. Winsteps® was used for analysis. Model determined
scale robustness in terms of unidimensionality, additivity
and functioning of the rating scale. RESULTS: Analyses
found person separation index of 1.86 with reliability of
0.77. The mean patient measure (0.69 logit) was greater
than mean difficulty of items (0.00 logit) implying patient
ability was greater than item difficulty. On average, or-
dering of items found item ‘physician instructed patients
on home steroid treatment’ (STETX) had the highest
logit measure of 0.69, however it misfitted the model.
Item ‘physician asked about smoking habits’ (ASKSMOK)
had lowest measure of 0.70 logits. Fit statistics revealed
high infit and outfit mean square (MNSQ) values (1.4) for
16 patients. Seven items had MNSQ values within desired
range of 0.6–1.4. CONCLUSIONS: Items exhibited ade-
quate reliability in separating persons, but they displayed
ceiling and floor effects in measurement. Some evidence of
construct validity was established since only one item misfit-
ted the model. Item STETX was the most difficult to en-
dorse (higher on construct), since it might not be applicable
to all, but severe asthmatics. Item ‘ASKSMOK’ was easiest
to endorse, probably because it is a standard asthma care
question. Nevertheless, misfitting persons implied inappro-
priate measurement of some patient attitudes. Thus, some
plausibility in the unidimensionality and validity of the scale
existed, and it exhibited moderate scaling properties.
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